LRP1B also plays a role in removing β-amyloid across the blood–brain barrier [26], and its reduced or absent expression may result in decreased clearance of β-amyloid and ApoE/α2-macroglobulin complexes, thereby increasing the risk of Alzheimer’s disease. Here, APOE is linked to Alzheimer disease.